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A B S T R A C T
Objectives: Understanding the proportion of pandemic deaths captured as ‘laboratory-confirmed’ deaths
is crucial. We assessed the ability of laboratory-confirmed deaths to capture mortality in the EU during
the 2009 pandemic, and examined the likelihood that these findings are applicable to the SARS-CoV-2
pandemic.
Methods: We present unpublished results from the Global Pandemic Mortality (GLaMOR) project, in
which country-specific mortality estimates were made for the 2009 influenza H1N1p pandemic. These
estimates were compared with laboratory-confirmed deaths during the 2009 pandemic to estimate the
ability of surveillance systems to capture pandemic mortality.
Results: For the 2009 influenza H1N1p pandemic, we estimated that the proportion of true pandemic
deaths captured by laboratory-confirmed deaths was approximately 67%. Several differences between
the two pandemics (e.g. age groups affected) make it unlikely that this capture rate will be equally high
for SARS-CoV-2.
Conclusion: The surveillance of laboratory-confirmed deaths in the EU during the 2009 pandemic was
more accurate than previously assumed. We hypothesize that this method is less reliable for SARS-CoV-2.
Near-real-time excess all-cause mortality estimates, routinely compiled by EuroMOMO, probably offer a
better indicator of pandemic mortality. We urge more countries to join this project and that national-
level absolute mortality numbers are presented.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
On March 11, 2020 the World Health Organization (WHO)
characterized COVID-19, caused by SARS-CoV-2, as a global
pandemic (WHO, 2020a). Understanding the pandemic’s mortality
impact is critical to the public health response. It is clear that the
number of laboratory-confirmed deaths is growing rapidly, but it is
not clear what proportion of the true number of pandemic deaths
the laboratory-confirmed count represents, because some deaths
caused by the virus may instead be attributed to underlying
diseases, while others may be attributed to COVID-19 without
laboratory confirmation.
Similar questions arose during the 2009 H1N1p influenza
pandemic (WHO, 2009; Briand et al., 2011). Countries were asked
to report laboratory-confirmed pandemic cases and deaths to
WHO (Briand et al., 2011). Such data are not typically used to
monitor seasonal influenza activity. Instead, most European
countries monitoring influenza cases rely on syndromic commu-
nity- and/or hospital-based surveillance systems and laboratory
data (Paget et al., 2007). Retrospective data analyses periodically
assess the mortality impact of seasonal influenza at a country,
regional, and global level (Iuliano et al., 2018; Paget et al., 2019).
During the H1N1p pandemic, ECDC published a daily update of
laboratory-confirmed H1N1p cases and deaths (ECDC, 2009). Two
later publications (Dawood et al., 2012; Simonsen et al., 2013),
using different methods to estimate the regional and global
mortality burden of H1N1p, concluded that only about 10% of the
true global excess mortality burden had been captured by directly
counting laboratory-confirmed pandemic deaths. One of these
studies, the WHO-funded Global Influenza Mortality Burden
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rder to generate regional and global mortality burden estimates
Simonsen et al., 2013).
Here we compare the GLaMOR country-level estimates for the
U (including the UK) with the laboratory-confirmed H1N1p
eaths reported to ECDC through January 2010. We discuss these
ndings in the context of the debate about laboratory-confirmed
OVID-19 deaths and the current pandemic’s true mortality
urden.
indings
The final 2009 WHO H1N1p pandemic update, published on
ugust 6, 2010, stated that 18 449 laboratory-confirmed pandemic
(H1N1) deaths had been reported globally (WHO, 2010). In
ontrast, the GLaMOR project put the number of influenza-
ssociated respiratory excess deaths about an order of magnitude
igher, at 123 000–203 000 globally (Simonsen et al., 2013). This
as in broad agreement with the second excess mortality
odeling study by CDC, estimating 201 200 (105 700–395 600)
ssociated respiratory deaths, with an additional 83 300 (46 000–
79 900) associated cardiovascular deaths (Dawood et al., 2012).
hese estimates show that laboratory-confirmed mortality sur-
eillance only captured approximately 10% of all global H1N1p-
ssociated mortality and thus greatly underestimated the actual
urden.
Though not previously published, the GLaMOR project gener-
ted single-country estimates. These add up to an estimated 3369
range 2695–4031) influenza-associated deaths in the EU (includ-
ng the UK). As of January 18, 2010, ECDC had recorded a total of
269 laboratory-confirmed H1N1p deaths in the EU, of which half
ere from four countries: UK (16%), France (13%), Spain (12%) and
taly (9%) (ECDC, 2010). For the entire EU region, national
aboratory-based mortality surveillance captured 67% of these
andemic deaths, showing wide variation between countries, with
greement ranging from –80% to +47% (Table 1).
Discussion
Our analysis shows that laboratory-confirmed H1N1p deaths in
Europe were not wildly different from excess mortality estimates,
despite variability between EU countries. In the case of the ongoing
SARS-CoV-2 pandemic, however, there are reasons to believe that
laboratory-confirmed death surveillance may be a less accurate
estimate of COVID-19 mortality. First, the sheer scale of the current
pandemic is far larger: November 11, 2020, 254 459 COVID-19
deaths had been reported to ECDC, compared with 2269 deaths
overall during the H1N1p pandemic (ECDC, 2010, 2020). The age
groups with the highest mortality are also different, which might
cause serious case ascertainment issues. For example, a recent
study estimated that in five EU countries (Belgium, France, Ireland,
Norway, and Spain) approximately 42–57% of COVID-19 deaths
have occurred in ‘care homes’, where testing appears to occur less
systematically (Comas-Herrera et al., 2020); interestingly, in
Belgium all deaths of those previously experiencing clinical
COVID-19 symptoms in nursing homes have been attributed to
COVID-19 without laboratory confirmation (Sciensano, 2020).
Meanwhile, shortages have prevented widespread testing of
suspected deaths, as urged by WHO (WHO, 2020b). Together,
these factors are likely to cause a far lower capture rate for COVID-
19 deaths in the confirmed tally, and inconsistent measurement
across the EU region (Leon et al., 2020). Though the progressive
increase in testing capacity for contact tracing purposes could
introduce important time-dependent biases in mortality surveil-
lance, it may have also raised the proportion of deaths captured,
which could lead to more reliable figures over time.
Optimal public health policies in response to the pandemic are of
the highest importance, and accurate COVID-19 burden estimates
(including deaths) are essential for making the best possible
decisions. Currently, most populations are still susceptible, and
with no vaccine the economic disruption of the measures currently
available to contain the spread of the infection (i.e. more or less
restrictive social distancing) will bring a huge socio-economic cost.
able 1
umber of deaths in the EU during the 2009 influenza pandemic and the estimated net capture rate.
Country Respiratory deaths




European Union Austria 74 24 –67%
Belgium 86 17 –80%
Bulgaria 126 35 –72%
Croatia 34 26 –23%
Czechia 105 77 –27%
Denmark 43 30 –29%
Finland 31 41 +31%
France 224 290 +30%
Germany 205 178 –13%
Greece 141 93 –33%
Hungary 136 57 –58%
Ireland 39 22 –43%
Italy 489 210 –57%
Latvia 26 31 +18%
Lithuania 53 19 –64%
Netherlands 133 54 –59%
Poland 260 138 –47%
Portugal 105 83 –21%
Romania 425 107 –75%
Slovakia 65 38 –42%
Spain 208 271 +31%
Sweden 70 25 –64%
UK 246 362 +47%
Otherb 48 41 +17%
Total 3369 2269 –33%
a Lower-bound 2009 estimate determined by proportionally projecting the under-65 age group estimate to all ages, using data from laboratory surveillance indicating that
5% of confirmed pandemic deaths occurred in the under 65 age group (Simonsen et al., 2013).
b Countries with fewer than 20 estimated deaths during the 2009 pandemic (Cyprus, Estonia, Luxembourg, Malta, Slovenia).
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data on SARS-CoV-2 mortality are needed. This is where studies of
excess all-cause mortality can help. Several studies in Italy and
Spain have shown large numbers of excess deaths in certain cities
and regions (Economist, 2020). While the number of laboratory-
confirmed deaths is dependent on testing capacity and policy
choices, all-cause mortality is free of such bias, as it is consistently
registered for all deaths. The excess mortality approach has its own
limitations and can overestimate the mortality burden attributed
to the virus (Li et al., 2018). However, excess all-cause mortality
calculated in a timely fashion potentially provides the most
objective estimate of the mortality burden of a pandemic. If all-
cause mortality suddenly far exceeds the historical baseline when
the pandemic arrives, as it has during the COVID-19 period, one can
be reasonably sure the pandemic is to blame.
Fortunately, the EuroMOMO network, based at the Statens
Serum Institut in Copenhagen, collects timely age-specific
mortality data from 24 European countries on a weekly basis.
Created in 2009, both to monitor seasonal influenza mortality and
for pandemic preparedness and response (Mazick et al., 2010),
EuroMOMO publishes aggregate numbers of deaths for the
entire region, adjusted for incomplete data. These timely
estimates, created using a common mathematical algorithm, are
standardized and presented with z-scores. This is a major asset,
allowing for comparison of weekly differences across countries
(EuroMOMO, no date).
The EuroMOMO surveillance system is a valuable resource for
understanding pandemic mortality. For example, the data show
clearly that no excess mortality is observable in children and young
adults. Because EuroMOMO uses a common mathematical
algorithm to compute the COVID-19 burden for Europe, measures
of excess mortality and impact are standardized and can be
compared across countries. This standardization allows calculation
and plotting of z-score graphs to easily see which countries have
experienced high COVID-19 mortality and which have not.
It is of great public health interest to see how these differences
between countries evolve over the following weeks and months,
and on this basis we encourage all WHO Euro countries to
contribute mortality data to EuroMOMO. Furthermore, we urge
participating countries to explore the possibility of allowing
EuroMOMO to present absolute mortality numbers and population
rates (per 100 000) for individual countries, which would be of
considerable added value (Leon et al., 2020). Doing so could
provide public health and government policy makers with useful
insights as they seek to manage the COVID-19 pandemic’s terrible
human and economic burden.
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